Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: type 1 diabetes

Can Lupus Be Prevented? Research Reveals Clues to Who’s Most Likely to Transition to Classified Disease

Susan Bernstein  |  February 25, 2020

How does a patient transition from health to active SLE? This question is the crux of the research conducted by Judith A. James, MD, PhD, and colleagues…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:2019 ACR/ARP Annual Meetingenvironmental factorgeneticSLEsystemic lupus erythematosus (SLE)

Low-Dose Methotrexate Can Cause Adverse Effects

Will Boggs, MD  |  February 19, 2020

NEW YORK (Reuters Health)—Low-dose methotrexate can be associated with gastrointestinal, pulmonary, infectious, hematologic and other adverse effects, according to an analysis of the Cardiovascular Inflammation Reduction Trial (CIRT). “Methotrexate is not a benign drug, even at dosages used for rheumatic diseases,” Daniel H. Solomon, MD, MPH of Brigham and Women’s Hospital, Boston, tells Reuters Health…

Filed under:Drug Updates Tagged with:adverse eventsMethotrexate

Sodium-Glucose Cotransporter-2 Inhibitors May Decrease Gout Risk in Some Patients

Lara C. Pullen, PhD  |  February 19, 2020

Recent research assessed the risk of gout in patients with type 2 diabetes mellitus prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with those prescribed a glucagon-like peptide-1 (GLP-1) agonist. The study found patients on the SGLT2 inhibitor had a lower rate of gout, suggesting SGLT2 inhibitors may actually reduce the risk of gout among this patient population…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:GoutSGLT2 inhibitorssodium-glucose cotransporter-2 (SGLT2) inhibitorstype II diabetes

A Public Health Approach to Arthritis: Experts Continue to Raise Awareness of Arthritis Burden

Thomas R. Collins  |  February 12, 2020

Public health agencies have been raising the profile of arthritis…

Filed under:Professional Topics Tagged with:ArthritisburdenCDCpublic health

The Care & Treatment of Myositis: Creatinine Kinase Level Isn’t Gospel & Other Recommendations

Thomas R. Collins  |  January 28, 2020

During a session at the 2019 ACR/ARP Annual Meeting, Lisa Christopher-Stine, MD, MPH, provided valuable recommendations and practical insights into the care and treatment of myositis patients…

Filed under:ConditionsMyositis Tagged with:2019 ACR/ARP Annual MeetingmyositisTreatment

New Draft Gout Guideline Released

Susan Bernstein  |  November 20, 2019

ATLANTA—The authors of the new draft ACR treatment guideline for the management of gout presented the draft guideline on Nov. 13 at the 2019 ACR/ARP Annual Meeting. Based on evidence from more than 130 published studies, there are 42 recommendations, of which 16 were strong, including 27 for urate-lowering therapy (ULT) management, 13 of which…

Filed under:Clinical Criteria/GuidelinesConditionsGout and Crystalline Arthritis Tagged with:2019 ACR/ARP Annual MeetingGout

Case Report: Tumor Treatment Unleashes Autoimmunity

Shuwei Wang, MD, Gulam A. Manji, MD, PhD, & Anca D. Askanase, MD  |  November 17, 2019

Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) axes have revolutionized therapy and improved survival in advanced cancers. However, these immune system modulators also lead to immune-related adverse events (IRAEs).1,2 In clinical trials, IRAEs mainly involved the gastrointestinal tract, skin, endocrine glands, liver and lung,…

Filed under:ConditionsMyositis Tagged with:CancerCheckpoint Inhibitorsdurvalumabendocrine diseasemyositis

A CT of the abdomen demonstrated numerous hypodense lesions present in both lobes of the liver, with the largest lesion measuring 2.0 x 3.1 cm.

Case Report: A Patient with Gout Develops Granulomatous Hepatitis

Raj Vachhani, MD, & Angelo L. Gaffo, MD, MSPH  |  November 16, 2019

Case Presentation A 45-year-old man with crystal-proven gout, poorly controlled diabetes and chronic kidney disease was lost to follow-up for six years and presented back to the VA clinic in the midst of a gout flare. He stated he had continued taking 100 mg of allopurinol daily, but his serum urate level was 13.8 mg/dL….

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Allopurinolgranulomatous hepatitis

Case Report: Cardiac Tamponade in a Rheumatoid Arthritis Patient

Case Report: Cardiac Tamponade in a Rheumatoid Arthritis Patient

Sirajum Munira, MD, Mamta Sherchan, MD, & Christopher Collins, MD, FACR  |  October 18, 2019

Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease. Although RA develops its central pathology within the synovium of diarthrodial joints, many non-articular organs can be involved, particularly in patients with severe joint disease.1 Although most patients are asymptomatic, cardiac involvement is relatively common and includes rheumatic heart nodules, pericarditis (30–50%), pericardial effusion and…

Filed under:ConditionsRheumatoid Arthritis Tagged with:cardiac tamponadecase reportFellows

What Causes Knee, Hip & Hand Osteoarthritis

Arthritis & Rheumatology  |  September 25, 2019

Funck-Brentano et al. hypothesized that causal associations for osteoarthritis (OA) may differ by site, and they undertook this study to identify causal risk factors of knee, hip and hand OA.

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis & Rheumatologyhand osteoarthritishipkneeKnee Osteoarthritis (OA)osteoarthritis (OA)Research

  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 29
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences